The catch: legal and regulatory certainty is reduced. Retatrutide was by no means within the FDA drug shortage list (because it was never approved), so compounders offering it operate less than extra tenuous lawful framing than those who dealt with semaglutide or tirzepatide throughout the 2023–2024 shortages. Pricing may change as enforcement ev